Nehal M. Ramadan
Hepatic insulin resistance and related obesity: highlighting the ameliorative role of nutraceuticals, dietary intervention, and pharmaceuticals.
Ramadan, Nehal M.; Barbosa, Priscila O.; Abo El-Magd, Nada F.; Eraky, Salma M.; Al-Gayyar, Mohammed M.H.
Authors
Priscila O. Barbosa
Nada F. Abo El-Magd
Salma M. Eraky
Mohammed M.H. Al-Gayyar
Abstract
Insulin resistance (IR) is the unifying denominator of all obesity-related metabolic abnormalities. It possesses a definite higher risk of developing type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). NAFLD is intimately linked to an accumulation of detrimental oxidative intermediates, which in turn promote insulin receptor substrates serine/threonine phosphorylation and ultimately block hepatic insulin signalling, and hepatic IR. The causal relationship between hepatic IR and NAFLD is bidirectional, and hepatic IR itself is "selective" in terms of resisting only insulin's suppressive effects on glucose production while keeping those enhancing hepatic lipogenesis intact. The present Research Topic aims to highlight the effect of natural compounds, dietary intervention, and synthetic drugs on hepatic IR and disorders related to obesity.
Citation
RAMADAN, N.M., BARBOSA, P.O., ABO EL-MAGD, E.F., ERAKY, S.M. and AL-GAYYAR, M.M.H. 2023. Hepatic insulin resistance and related obesity: highlighting the ameliorative role of nutraceuticals, dietary intervention, and pharmaceuticals. Frontiers in Pharmacology [online], 14, article 1266168. Available from: https://doi.org/10.3389/fphar.2023.1266168
Journal Article Type | Editorial |
---|---|
Acceptance Date | Jul 28, 2023 |
Online Publication Date | Aug 7, 2023 |
Publication Date | Dec 31, 2023 |
Deposit Date | Sep 1, 2023 |
Publicly Available Date | Sep 1, 2023 |
Journal | Frontiers in pharmacology |
Electronic ISSN | 1663-9812 |
Publisher | Frontiers Media |
Peer Reviewed | Peer Reviewed |
Volume | 14 |
Article Number | 1266168 |
DOI | https://doi.org/10.3389/fphar.2023.1266168 |
Keywords | Dietary intervention; Inflammation, drugs; Natural compounds; Hepatic insulin resistance; Obesity |
Public URL | https://rgu-repository.worktribe.com/output/2052353 |
Files
RAMADAN 2023 Hepatic insulin resistance (VOR)
(595 Kb)
PDF
Copyright Statement
© 2023 Ramadan, Barbosa, Abo El-Magd, Eraky and Al-Gayyar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Downloadable Citations
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search